Loading patent…
AssigneeRegenerative Research Foundation
InventorsJeffrey Stern, Sally Temple Stern, Timothy Blenkinsop
Estimating the term…
Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative vitreoretinopathy, preretinal fibrosis, vitreomacular traction, tractional retinal detachment, and phthsis bulbi, cystoid macular edema (CME) arising from intraocular inflammation due to uveitis, vasculitis, trauma, surgery, and collagen vascular disease (e.g., Behcets disease or sarcoidosis), and age related macular degeneration.
A method for inhibiting or reversing epiretinal membrane (ERM) formation in a patient, the method comprising administering to a patient suffering from or at risk of developing ERM an amount of nicotinamide effective for inhibiting proliferation of retinal pigmented epithelial (RPE) cells.
A method for inhibiting or reversing epithelial mesenchymal transition (EMT) in a patient, the method comprising administering to a patient suffering from or at risk of developing EMT an amount of nicotinamide effective for maintaining or inducing normal RPE cell morphology.
A method for treating a retinal disease or condition associated with cystoid macular edema (CME) in a patient, the method comprising administering to a patient in need thereof an amount of nicotinamide effective for reducing leakage through tight junctions.
A method for inhibiting a pathologic condition associated with oxidative damage-induced RPE atrophy in a patient, the method comprising administering to a patient in need thereof an amount of nicotinamide effective for inhibiting stress-induced RPE drusen formation and/or stress-induced RPE cell death and/or RPE cell atrophy.
A method for inhibiting drusen in a patient, the method comprising administering to a patient in need thereof an amount of nicotinamide effective for stabilizing the RPE phenotype, thereby preventing overproduction of drusen protein and associated drusen.
A method for treating a patient suffering from or at risk of developing neovascular (wet or exudative) AMD, the method comprising administering to a patient in need thereof an amount of nicotinamide effective for stabilizing the RPE cell barrier to choroidal neovascular ingrowth.
Dependencies are inferred from the claim text.